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In clinical trials, elevated liver transaminase levels in patients taking lumacaftor/ivacaftor therapy were 
reported.  Our aim was to assess in clinical practice, whether F508del homozygous paediatric CF patients 
had a derangement of liver functions tests (LFTs) while on lumacaftor/ivacaftor therapy.  
 
Methods 
A retrospective chart review audit in a single CF centre.   
 
Results 
Thirty-nine (43%) patients out of 91 CF clinic patients met criteria to start treatment. We observed a 
statistically significant decrease in ALT, ALP, GGT and total bilirubin levels, and no change in AST levels 
during first 3 months of treatment. In two patients (5%) AST levels rose to greater than three times the 
upper limit of normal (ULN) during treatment, however, these levels then decreased with continued use. 
A similar trend of improved LFTs was seen in a subgroup of patients with pre-existing liver disease 
(6/15.4% of patients). No patients died or experienced hepatic encephalopathy. 
 
Conclusion  
Our results were unexpected and encouraging. They suggest that, although the clinical trials report a risk 
of derangement of LFTs, the risk appears to be low. 
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Cystic Fibrosis (CF) is a genetic, multi-system condition, with progressive lung disease resulting in early 
death1. Ireland has the highest incidence of CF in the world and one in 19 people carry a defective gene2. 
The most common Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) variant is F508del and 
in Ireland 55% of patients are F508del homozygous2.  
 
The combination of lumacaftor (a CFTR corrector) and ivacaftor (a CFTR potentiator) is licensed for the 
treatment of patients with CF who are homozygous for the F508del mutation. It became available in 
Ireland to patients 12 years and older in 2017, and to patients aged 6-11 years in early 2018. Prior to this, 
select patients, with advanced disease, were able to receive the drug on a “managed access programme” 
(MAP). In clinical trials, serious adverse reactions related to elevated liver transaminase levels were 
reported 3-5. Consequently, it is recommended that serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and bilirubin are monitored prior to initiating the drug, and every three months 
for the first year of treatment, then annually. In patients with raised LFTs at baseline, more frequent 
monitoring is recommended, but not defined. Patients with significant liver disease were excluded from 
the original clinical trials3-5. The aim of this study was to ascertain if F508del homozygous paediatric CF 
patients had a derangement of LFTs while on lumacaftor/ivacaftor therapy in the first year after 




This study was conducted at the University Hospital Limerick (UHL) Paediatric CF unit. This is a 
retrospective chart review performed as an audit process in July 2018. Homozygous F508del patients 
attending the unit, who fulfilled the criteria to start lumacaftor/ivacaftor combination therapy, were 
identified from the clinic patient database, and their medical notes were reviewed.  
 
The following variables were extracted from the medical records for each patient: date of birth, gender, 
date and age at initiation of treatment, cohort (12 years and older, 6-11 years old), dose cohort. Patients 
aged 12 years and older started on the higher dose (lumacaftor 200mg/ ivacaftor 125mg, two tablets 
twice daily) and patients aged 6-11 years started on the lower dose (lumacaftor 100mg/ivacaftor 125mg 
two tablets twice daily). In an effort to reduce the risk of chest discomfort and transient decrease in lung 
function at the initiation of treatment, we instigated a local policy of starting with one tablet twice daily 
for the first week, increasing to two tablets in the morning, and one in the evening for the second week, 
before increasing to the final, steady state dosing of two tablets twice daily from the third week onwards. 
The LFTs included: AST, ALT, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and bilirubin. 
Results at baseline, three, six, nine and 12 months of treatment were extracted.  At the time of our study, 
none of our patients had been on treatment for longer than a year. To aid comparisons across time, 
blood levels taken within six weeks of a set time point were included in that time point (ie. three months 
+/- six weeks).  
 
Patients with pre-existing CF liver disease (CFLD) were also identified.  These patients had been assessed 
for, and diagnosed with, CFLD at the national CFLD specialist centre, at Our Lady’s Children’s Hospital 
Crumlin (OLCHC), Dublin. This sub-group had more frequent monitoring in the initial weeks after 
initiation of treatment. As the medication product leaflet does not describe a monitoring system for 
patients with CFLD, a local protocol was devised with the following time intervals: at baseline, then at the 
two, four, six and 12 weeks, and, if stable, patients were followed as per the standard recommendations 
of every third month, until 12 months and then annually.   
 
Data was analyzed using SPSS.  Excel was used to graph the data. Distribution was determined using a 
combination of histogram and box-plot analysis and the Shapiro-Wilk test for normality (p-value <0.05). If 
the data had a skewed distribution, then it was compared using the Wilcoxon signed-rank non-parametric 
test for related data, with each patient compared to their previous level. If the data were normally 
distributed, then a paired samples t-test was used to compare the data. A p-value <0.05 was deemed 





From a total clinic of 91 paediatric patients with CF we identified 42 (46%) who were F508del 
homozygous and over six years of age. Three children did not start treatment (7%); one (2%) was post 
lung transplant, one was listed for liver transplant (2%), and one was recruited into a tezacaftor/ivacaftor 
clinical trial (2%). 
 
There were 39 patients who fulfilled the criteria to start treatment at time of study in July 2018. See 
Table 1 for patient demographics. All 39 initiated, and continued, treatment during the study period. No 
patients died, and none experienced liver failure, hepatic encephalopathy or jaundice during the study. 
Two patients received treatment as part of the MAP (5%).  The patients aged 12 years and older were 
started on the higher dose (lumacaftor 200mg/ ivacaftor 125mg) and the patients aged 6-11 years were 
started on the lower dose (lumacaftor 100mg/ivacaftor 125mg). Prior to initiation of treatment, all 
patients had LFTS checked, however, two patients (5%) had no AST level reported due to lab error. There 
were 34 patients (87%) who had completed three months of treatment, 18 (46%) completed six months, 
16 (41%) completed nine months and 13 (33%) completed 12 months at data collection.  
 
 
Table 1: Demographics of CF patients at UHL Paediatric CF clinic. CFLD: Cystic Fibrosis Liver disease. 
 
 All patients (n=39) CFLD (n=6)  
Average age (years) 11.1 12.3 
Male sex 21 (54%) 4 (67%) 
>12yo 18 (46%) 4 
6-11yo 20 (51%) 2 
 
 
Figure 1 displays the median levels for AST, ALT, ALP, GGT at each timepoint.  AST, ALT, GGT all remained 
steady and within the normal reference range, with ALP having an overall graphical trend towards 
normalization of values.   
 
 
Figure 1: AST, ALT, ALP, GGT median levels graphed at each time point.  Median was used due to skewed 






Figure 2 displays the total bilirubin levels for all patients and those specifically with CFLD.  Overall, the 








Figure 2: Bilirubin levels graphed at each timepoint. CFLD patients had closer LFT monitoring during the 
first 6 weeks of treatment. The remaining patients did not have levels checked during this time. Bilirubin 
levels from all patients had a normal distribution, thus the mean was used for analysis. The data for the 6 






We had adequate numbers of test results only at baseline and at three months for all patients to perform 
a statistical analysis. The ALT, AST, ALP and GGT data were determined to have a skewed distribution 
based on histogram and boxplot distributions and the Shapiro-Wilk test for normality. Thus, the data 
were compared using the Wilcoxon Signed Rank Test. The total bilirubin levels were determined to have 
a normal distribution, thus a paired samples t-test was applied. Overall, we found our patients had a 
statistically significant decrease in ALT, ALP, GGT  and total bilirubin levels, and no statistically significant 
change in AST levels as follows; the median LFT values (IU/L) at baseline (pre-treatment) and at three 
months, respectively, were : ALT 34 and 30 (p-value 0.016), ALP 288 and 213.5 (p-value 0.001), GGT 12 
and 12 (p-value 0.002), and AST 37 and 33.5 (p-value 0.076). The mean bilirubin levels (umol/L) at 
baseline (pre-treatment) and at three months on treatment for all patients was 8.26 and 6.36 
respectively, (p value: 0.002). Two patients (5%) had increased AST levels during treatment > 3 x ULN, 
however, these levels then decreased with continued use. None of our patients had LFTs > 8 x ULN, or > 5 
x ULN during treatment, and none had ALT, ALP or total Bilirubin levels > 3 x ULN during treatment.   
 
 
The data for six patients with pre-existing CFLD were extracted and were also analyzed separately. See 
table 1 for demographic details. Results were similar to those without established CFLD. The median 
levels at each time point for bilirubin and AST, ALT, ALP, GGT are graphically depicted in Figures 2 and 3, 
respectively and demonstrate a clear graphical trend of improving LFTs across all parameters. We could 
not determine statistical significance in CFLD population due to the limited number of patients. 
 
Figure 3: AST, ALT, ALP, GGT median levels graphed at each time point for CFLD patients only (n=6).  
Median was used due to skewed distributions. Normal values: AST (5-34 IU/L), ALT (10-55 IU/L), ALP (47-








We present the first “real world” study of the short-term effect of lumacaftor / ivacaftor combination 
therapy on the liver function status of children with CF. Our results were unexpected and encouraging. 
They suggest that, although the clinical trials raised a concern that commencing a child on this new CFTR 
modulator therapy came with a significant risk of derangement of LFTs, the risk appears to be low and 
therapy may actually help improve LFTs.   
 
 
CFLD is a significant complication of CF primarily evolving in the school age years and can have a 
detrimental effect on morbidity and mortality 6, 7. To date there has been no intervention which has 
demonstrated efficacy in altering the course of CFLD 6, 7. Pre-existing CFLD was an exclusion criteria for 
the clinical trials, however it is not a contra-indication to prescribing lumacaftor / ivacaftor combination 
therapy. Although our numbers are small, with just six patients (15%) with significant CFLD, the trends 
observed are encouraging. Dempsey et al, found similar improvements in LFTs in a small number (n=7) of 
patients with CFLD, but did not assess the effect of lumacaftor / ivacaftor on those without CFLD8. Firstly, 
it appears these patients can tolerate the treatment safely. Secondly, and perhaps more encouragingly; 
this may represent the first evidence of an intervention that can improve LFTs in patients with CFLD. 
Further observation is required to ascertain if this is translated into improvements in liver synthetic 
function and the manifestations of portal hypertension, such as splenomegaly and oesophageal varices.  
 
Similar to many other medications lumacaftor / ivacaftor combination therapy may indeed come with a 
risk of liver injury. Drug induced liver injury (DILI) is the most common reason for withdrawing an agent 
from the market, and / or issuing warnings and modifications for their use9-11. RUCAM (Roussel Uclaf 
Causality Assessment Method) is a well-established methodology to assess causality in suspected DILI9, 12, 
13. DILI is defined as, the now familiar, ALT levels above 5 × ULN and/or ALP levels greater than 2 × the 
ULN9, 12, 13. In addition the Hy’s law predicts a 10% mortality (range 5-50%) when hepatocellular DILI is 
associated with a serum bilirubin level of ≥ 3 ULN14. However, determining causality of DILI remains 
complex and challenging with the majority of cases classed as “idiosyncratic” – essentially unexpected 
and unexplained10. Relevant to this discussion is the fact that, in the liver, CFTR is not expressed in 
hepatocytes, but exclusively in cholangiocytes15, 16. Defective chloride channel function can result in 
inspissated secretions that obstruct biliary flow, peri-biliary fibrosis, and for some patients progression 
from focal to multilobular biliary cirrhosis16-20. Onset of clinically significant disease is typically during the 
first decade of childhood21, 22. One might speculate that there are two separate processes at play here. 
The medication may come with a risk of liver injury, by a mechanism yet to be clearly defined, but may 
also come with a marginal, but potentially important, improvement in CFLD by improving CFTR 
functioning at the apex of cholangiocytes lining the bile ducts. Consistent with this theory, Kutney et al, 
demonstrated, using magnetic resonance imaging proton density fat fraction analysis, that lumacaftor / 
ivacaftor therapy was associated with reduced hepatic steatosis. Interestingly, the study excluded 
patients with CFLD or persistently elevated liver enzymes23.  
 
Our study has several limitations. It is a single centre study, with a small sample size. We had adequate 
numbers to perform a statistically valid comparison of baseline and three-month data, however the 
ability of this dataset to make inferences about the wider CF population is limited, and the findings 
should be viewed with caution. Also, many of the time points have missing data. This illustrates the 
challenges of applying a stringent surveillance system for adverse events requiring frequent blood draws 




Although the results of our study are encouraging, continued vigilance is required. On the basis of these 
findings we plan to expand our study to involve greater numbers, across multiple sites, and to include 
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